Pyrido [1,2-a]pyrimidine derivatives

Abstract: Pyrido[l,2-a]pyrimidine derivatives of the general formula [I] and their physiologically acceptable salts are provided: where R is a hydrogen atom, a halogen atom or a methyl group, and n is a whole numter of 0, l or 2. The pyrido[l,2-a]-­ pyrimidine derivatives and their salts exhibit an excellent antagonistic effect on the slow-reacting substance of anaphylaxis and, therefore, are useable for the treatment of allergic diseases.

Description: This invention relates to pyrido[l,2-a]pyrimidine derivatives and physiologically acceptable salts thereof, a process for preparing such compounds, and pharmaceutical compositions containing such a compound as an active ingredient. The pyrido[l,2-a]pyrimidine derivatives and physiologically acceptable salts thereof in accordance with the present invention have a marked antagonistic effect on the "slow-reacting substance of anaphylaxis"(hereinafter abbreviated as SRS-A) and, therefore, can be used in the treatment of Type I allergic diseases induced by SRS-A. SRS-A is strongly effective in causing contraction of smooth muscle and constitutes a substance responsible for Type I allergic diseases, particularly bronchial asthma and allergic rhinitis [Quarterly Journal of Experimental Physiology, Vol. 30, p. l2l, l940]. Leukotriene D₄ has been found to be a representative active component of this substance and the presence of an inhibitory effect on the in vivo activity of leukotriene D₄ is now considered to be a criterion of the usefulness of a drug for the treatment of Type I allergic diseases induced by SRS-A [Nature, Vol. 288, p. 484, l980]. Drugs useful for the treatment of Type I allergic diseases induced by SRS-A are roughly divided into two types: drugs of the SRS-A release suppression type which act to prevent the release of SRS-A from mast cells or basophils and thereby inhibit its activity indirectly, and drugs of the SRS-A antagonistic type which act to antagonize the released SRS-A in the living body and thereby inhibit its activity directly. However, drugs of the SRS-A release suppression type are inherently used for the purpose of preventing the induction of allergic attacks by SRS-A and generally tend to lack effectiveness immediately after the onset of an attack. That is, they often fail to exhibit the so-called "rapid-acting property". In recent years, therefore, it has been eagerly desired from the viewpoint of an immediate effect on allergic attacks to develop a satisfactorily effective drug of the SRS-A antagonistic type. 9-Methyl-3-(lH-tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-­ 4-one potassium salt (hereinafter abbreviated as Compound TBX) is a conventionally known pyridopyrimidine compound and it has been reported that this compound is useful for the prevention of Type I allergic reactions (Japanese Patent Laid-Open No. 36294/'79). However, a subsequent study has revealed that Compound TBX belongs to the SRS-A release suppression type (Japanese Journal of Allergology, Vol. 33, No. 9, p. 728, l984). Moreover, a confirmatory experiment conducted by the present inventors has demonstrated that Compound TBX has no antagonistic effect on SRS-A as represented by leukotriene D₄. Accordingly, the present inventors have made an exhaustive study in the search for compounds antagonizing the in vivo activity of SRS-A and, in particular, leukotriene D₄. As a result, a novel compound having a marked antagonistic effect on leukotriene D₄ has surprisingly been discovered among compounds containing a pyrido[l,2-a]pyrimidine ring analogously to Compound TBX. The present invention has been completed on the basis of this discovery. According to one feature of the present invention, there is provided a pyrido[l,2-a]pyrimidine derivative of general formula [I]: where R is a hydrogen atom, a halogen atom or a methyl group, and n is 0, l or 2, or a physiologically acceptable salt thereof. According to another feature of the present invention, there is provided a process for preparing pyrido[l,2-a]­ pyrimidine derivatives of the above general formula [I] and physiologically acceptable salts thereof. According to yet another feature of the present inven­ tion, there is provided a pharmaceutical composition useful for the treatment of allergic diseases containing, as an active ingredient, a pyrido[l,2-a]pyrimidine derivative of the above general formula [I] or a physiologically acceptable salt thereof. The pyrido[l,2-a]pyrimidine derivatives represented by the above general formula [I] (hereinafter referred to briefly as the present compounds [I]) can be prepared by reacting a nitrile compound of general formula [II]: where R and n are as previously defined, with hydrazoic acid or a salt thereof. Useful salts of hydrazoic acid include alkali metal salts such as sodium azide, potassium azide, etc.; alkaline-­ earth metal salts such as calcium azide, magnesium azide, etc.; salts formed by reaction with other metals, such as aluminum azide, tin azide, titanium azide, etc., and salts formed by reaction with organic bases, such as ammonium azide, aniline azide, etc. Although such salts of hydrazoic acid may be used alone, alkali metal salts of hydrazoic acid should preferably be converted to aluminum azide, tin azide, ammonium azide, aniline azide or the like in the reaction system by using them in combination with a Lewis acid (such as aluminum chloride, tin chloride or the like) or a suitable salt (such as ammonium chloride, aniline hydrochloride or the like). The most preferable combination comprises sodium azide and aluminum chloride or ammonium chloride. Suitable reaction solvents include ethers such as tetra­ hydrofuran, dioxane, etc.; and polar solvents such as dimethylformamide, dimethyl sulfoxide, dimethylacetamide, hexamethylphosphorotriamide, etc. The reaction may be carried out by heating the reaction mixture at a temperature of 50 to l50°C for a period of time ranging from l minute to 72 hours. The present compound [I] prepared as above may be purified by recrystallization, by silica gel column chromatography, by converting the present compound [I] to a suitable salt and then neutralizing this salt to effect crystallization (hereinafter referred to as the crystalliza­ tion procedure), or by a combination of these procedures. Recrystallization solvents suitable for use in purifica­ tion by recrystallization include water, methanol, ethanol, n-propyl alcohol, isopropyl alcohol, dimethylformamide, dimethyl sulfoxide, hexamethylphosphorotriamide, acetic acid, acetonitrile, trifluoroacetic acid and tetrahydrofuran, as well as mixtures of two or more such solvents. Developing solvents suitable for use in purification by silica gel chromatography include various mixtures of a halogenated hydrocarbon (such as chloroform, dichloromethane or the like) and an alcohol (such as methanol, ethanol or the like). Salts suitable for use in the crystallization procedure include sodium salts, potassium salts, calcium salts, magnesium salts and ammonium salts, and suitable neutralizing agents include mineral acids such as hydrochloric acid, sulfuric acid, nitric acid, etc., and organic acids such as acetic acid, formic acid, etc. Reaction solvents suitable for use in this crystallization procedure include water and various mixtures of water and an alcohol such as methanol, ethanol, isopropyl alcohol, n-butyl alcohol or the like. Physiologically acceptable salts of the present compounds [I] can be prepared by reacting the corresponding compound [I] with an alkali metal or alkaline-earth metal hydroxide (such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide or the like), an alkali metal or alkaline-earth metal carbonate (such as sodium carbonate, potassium carbonate, calcium carbonate, magnesium carbonate or the like), an alcoholate of an alkali metal or an alkaline-­ earth metal (such as sodium, potassium, magnesium or the like), an organic amine (such as ethanolamine, methylephedrine or the like) or ammonia in water, an alcohol or a mixture thereof. Alcohols suitable for this purpose include methanol, ethanol, isopropyl alcohol, n-butyl alcohol and the like. The hydroxide, carbonate, alcoholate, organic amine or ammonia should be used in an amount of 0.5 to 6 moles, preferably 0.5 to 2 moles, per mole of the present compound [I]. The salt prepared as above may be purified by recrystalli­ zation, if necessary. Recrystallization solvents suitable for this purpose include water, methanol, ethanol, n-propyl alcohol, isopropyl alcohol, dimethylformamide, dimethyl sulfoxide, hexamethylphosphorotriamide, acetonitrile and tetrahydrofuran, as well as mixtures of two or more such solvents. The present compound [I] or physiologically acceptable salts thereof prepared in the above-described manner may be dried according to any of the conventional methods including warm­ ing, through-flow drying, freeze-drying and the like. The nitrile derivatives represented by the above general formula [II] can be prepared by condensing l mole of a compound of general formula [III]: where R and n are as previously defined and X is a chlorine or bromine atom, with l to 6 moles of 2,4-dihydroxy-3-n-­ propylacetophenone in the presence of an acid acceptor. Acid acceptors useful for this purpose include alkali metal carbonates such as sodium carbonate, potassium carbonate, etc., and alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, etc. In the reaction system, potassium iodide may also be present as a reaction accelerator. Suitable reaction solvents include methanol, ethanol, isopropyl alcohol, n-butyl alcohol, acetone, methyl ethyl ketone, diethyl ketone, cyclohexanone, dimethylformamide, dimethyl sulfoxide, mixtures of two or more such solvents, and mixtures of water and such solvents. The reaction is carried out by heating the reaction mixture at a temperature of 50 to ll0°C for a period of time ranging from l minute to 72 hours. The compounds represented by the above general formula [III] can be prepared (l) by halogenating a compound of the general formula [IV]: where R and n are as previously defined, with the aid of a halogenating agent such as thionyl chloride, phosphorus trichloride, phosphoryl chloride, phosphorus tribromide, phosphoryl bromide or the like, or (2) by halogenating and dehydrating a compound of the general formula [V]: where R and n are as previously defined, with the aid of a halogenating agent such as phosphoryl bromide, phosphoryl chloride, thionyl chloride or the like. Compounds of the above general formula [III] in which n is equal to 0 can also be prepared by halogenating a compound of the general formula [VI]: where R is as previously defined, with the aid of N-chloro­ succinimide or N-bromosuccinimide. The antagonistic effect on SRS-A of the present compounds [I] and physiologically acceptable salts thereof was tested according to the following experimental procedures using leukotriene D₄ which is a representative active component of SRS-A. The test compounds used for this purpose were the compounds enumerated below and considered to be typical examples of the present compounds [I] and physiologically acceptable salts thereof. The designation given in parentheses after the chemical name of each compound means its tentative name as used herein and corresponds to the respective one of the examples which will be described later. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-(lH-­ tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one (Example l). 7-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-(lH-­ tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one (Example 2). 8-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-(lH-­ tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one (Example 3). 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-7-bromo-­ 3-(lH-tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one (Example 4). 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-7-­ methyl-3-(lH-tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one (Example 5). 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-­ [(lH-tetrazol-5-yl)methyl]-4H-pyrido[l,2-a]pyrimidin-4-one (Example 6). 7-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-­ [(lH-tetrazol-5-yl)methyl]-4H-pyrido[l,2-a]pyrimidin-4-one (Example 7). 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-7-­ methyl-3-[(lH-tetrazol-5-yl)methyl]-4H-pyrido[l,2-a]pyrimidin-­ 4-one (Example 8). 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-[2-­ (lH-tetrazol-5-yl)ethyl]-4H-pyrido[l,2-a]pyrimidin-4-one (Example 9). 8-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-[2-­ (lH-tetrazol-5-yl)ethyl]-4H-pyrido[l,2-a]pyrimidin-4-one (Example l0). 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-7-bromo-­ 3-[2-(lH-tetrazol-5-yl)ethyl]-4H-pyrido[l,2-a]pyrimidin-4-one (Example ll). 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-(lH-­ tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one potassium salt (Example l2). 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-[2-­ (lH-tetrazol-5-yl)ethyl]-4H-pyrido[l,2-a]pyrimidin-4-one potassium salt (Example l3). (i) in vitro tests The antagonistic effect on leukotriene D₄ of the present compounds [I] and physiologically acceptable salts thereof was tested by using the terminal ileum excised from a male guinea pig of the Hartley strain. Specifically, the terminal ileum was suspended, under aerated conditions, in l0 mℓ of Tyrode's solution containing 5 × l0⁻⁷ M atropine and l × l0⁻⁶ M mepyramine. Then, a test compound and leukotriene D₄ (manufactured by Wako Junyaku Co., Ltd.) were successively added thereto with an interval of 30 seconds. After the lapse of 4 to 6 minutes, the degree of contraction of the ileum was measured with a Model TD-ll2S Isotonic Transducer (manufactured by Nippon Koden Co., Ltd.). The test compound and leukotriene D₄ were used in such amounts as to give concentrations of l0⁻⁹ to l0⁻³ g/mℓ and 0.3 ng/mℓ, respectively. The antagonistic effect on leukotriene D₄ of each test compound was evaluated in terms of the concentration of the test compound at which the ileum contraction reaction induced by leukotriene D₄ was inhibited by 50% (hereinafter referred to as IC₅₀). Specifically, at varying concentrations of each test compound, the percent inhibition of contraction was calculated from the measured degree of contraction of the ileum according to the following equation: On the basis of the data thus obtained, a dose-response curve was prepared and used to determine the IC₅₀ value of the test compound. The results thus obtained are shown in Table l. For purposes of comparison, the antagonistic effect on leukotriene D₄ of Compound TBX was tested in the same manner as described above and the result is also shown in Table l. Among the test compounds indicated, the compounds of Examples l, 6 and 9 were prepared according to procedure a described in the respective examples. As is evident from Table l, it may be recognized that the present compounds [I] and physiologically acceptable salts thereof exhibit a marked antagonistic effect on leukotriene D₄ which cannot be predicted from Compound TBX. (ii) In vivo tests Using male guinea pigs of the Hartley strain, weighing about 400 g, in groups of six, the inhibitory effect of the present compounds [I] and physiologically acceptable salts thereof on a Type I allergic reaction induced by leukotriene D₄ was tested in two dosage forms (i.e., by intravenous injection and by oral administration) according to the Konzett-Rössler procedure [Naunyn-Schmiederbergs Archiv für Experimentelle Pathologie und Pharmakologie, Vol. l95, p. 7l, l940]. Specifically, each guinea pig was anesthetized by intraperitoneal administration of l.5 g/kg of urethane and an incision was made in the neck to expose the trachea. To the exposed trachea was connected a respirator (with a ventilation volume of 5-7 mℓ, a respiration rate of 70 per minute, and a pulmonary load pressure of l0 cmH₂O; manufac­ tured by Ugo Basile Biological Research Apparatus Co.) by way of a cannula. The volume of air overflowing through the branch of the cannula was measured by means of a Model 7020 Bronchospasm Transducer (manufactured by Ugo Basile Biological Research Apparatus Co.) and recorded with a Model RM-6000 Polygraph (manufactured by Nippon Koden Co., Ltd.). Intravenous injection tests were carried out as follows: Each guinea pig was treated by intravenous injection of l mg/­ kg of gallamine triethiodide. Then, 20.0 to 6000.0 µg/kg of a test compound and 0.5 µg/kg of leukotriene D₄ were successively administered thereto through the cervical vein with an interval of 2 minutes. The volume of air overflowing as a result of the induced airway constriction reaction was measured. The test compound was used in the form of a solution in physiological saline containing sodium hydrogen carbonate or potassium carbonate. Oral administration tests were carried out as follows: l to 30 mg/kg of a test compound was orally administered to each guinea pig 90 minutes before anesthesia with urethane. Then, the anesthetized guinea pig was treated by intravenous injection of l mg/kg of gallamine triethiodide and administra­ tion of 0.5 µg/kg of leukotriene D₄ through the cervical vein. The volume of air overflowing as a result of the induced air­ way constriction reaction was measured. Both in the intravenous injection tests and in the oral administration tests, leukotriene D₄ was used in the form of a solution in physiological saline. Both in the intravenous injection tests and in the oral administration tests, the pharmacological effect on the Type I allergic reaction was evaluated in terms of the dose of the test compound at which the airway constriction reaction induced by leukotriene D₄ was inhibited by 50% (hereinafter referred to as ID₅₀), provided that ID₅₀ was expressed in µg/kg for the intravenous injection tests and in mg/kg for the oral administration tests. Specifically, at 4 to 6 different doses of each test compound ranging from 20.0 to 6000.0 µg/kg for the intravenous injection tests and from l to 30 mg/kg for the oral administration tests, the percent inhibition of the airway constriction reaction was calculated according to the following equation: Percent inhibition = × l00 where X is the ratio of the incremental volume of overflowing air measured in the leukotriene D₄-treated group to the incremental volume of overflowing air measured when the airway of the guinea pig is perfectly constricted, and Y is the ratio of the incremental volume of overflowing air measured in the test compound- and leukotriene D₄-treated group to the incremental volume of overflowing air measured when the airway of the guinea pig is perfectly constricted. On the basis of the data thus obtained, a dose-response curve was prepared and used to determine the ID₅₀ value of the test compound. The results thus obtained are shown in Table 2. For purposes of comparison, the ID₅₀ value of Compound TBX was determined in the same manner as described above in connection with the intravenous injection tests, except that its doses ranged from 5 to l0 mg/kg, and the result is also shown in Table 2. Among the test compounds indicated, the compounds of Examples l, 6 and 9 used in the intravenous injection tests were prepared according to procedure a described in the respective examples, and those used in the oral administration tests were prepared according to procedure b . As is evident from Table 2, it may be recognized that the present compounds [I] and physiologically acceptable salts thereof can antagonisticaily and markedly inhibit leukotriene D₄-induced Type I allergic reactions as represented by the airway constriction reaction. (iii) Toxicity test The acute toxicity (LD₅₀) of several typical examples of the present compounds [I] and physiologically acceptable salts thereof was tested on 5-weeks-old male ddY strain mice and male SD strain rats. For this purpose, the compounds of Examples l, 6 and 9 were selected as typical examples. For mice, the LD₅₀ values of these three compounds were not less than 4.0 g/kg when administered orally, and not less than l00 mg/kg when administered intravenously. For rats, their LD₅₀ values were not less than 4.0 g/kg when administered orally, and not less than 200 mg/kg when administered intravenously. As can be seen from the results of the above-described in vitro tests, in vivo tests and toxicity tests, the present compounds [I] and physiologically acceptable salts thereof are useful for the treatment of SRS-A induced Type I allergic diseases including, in particular, bronchial asthma and allergic rhinitis. They can also be used as anti-ulcer agents, anti-inflammatory agents or drugs for the treatment of ischemic heart diseases. The present compounds [I] and physiologically acceptable salts thereof may be admixed with physiologically inert solid or liquid pharmaceutical carriers to form pharmaceutical compositions. These compositions may have a variety of dosage forms including injectable solutions, tablets, capsules, powders, fine granules, granules, liquors, suspensions and emulsions. The pharmaceutical carriers can be any of various pharmaceutical carriers usually used in such dosage forms, and examples thereof include excipients, binders and disintegrants, such as corn starch, dextrin, α-, β- or γ-­ cyclodextrin, glucose, lactose, sucrose, methylcellulose, calcium carboxymethylcellulose, crystalline cellulose, magnesium stearate, sodium alginate, Witepsol W35, Witepsol E85, polyvinyl alcohol, light silicic acid anhydride, etc.; lubricants such as talc, stearic acid, waxes, hydroxypropyl­ cellulose, boric acid, etc.; coating agents such as shellac, cellulose acetate phthalate, polyvinyl acetal diethylamino­ acetate, etc.; solubilizing agents such as glycerol, propylene glycol, mannitol, etc.; emulsifying or suspending agents such as polyoxyethylene stearate, polyoxyethylene cetyl alcohol ether, gum arabic, polyvinylpyrrolidone, etc.; stabilizers such as sorbitol, Tween 80, Span 60, fats and oils, etc.; and various solvents. In the above-described pharmaceutical compositions, the present compound [I] or a pharmaceutically acceptable salt thereof should be contained in such an amount that the daily dose of the active ingredient is in the range of 0.002 to 60 mg/kg, preferably 0.02 to l0 mg/kg, for purposes of oral administration or in the range of l to l000 µg/kg, preferably l0 to 200 µg/kg, for purposes of intravenous injection. The present invention is further illustrated by the following Reference Examples, non-limiting Examples and Pharmaceutical Compositions. Reference Examples l.30 g (4.92 mmoles) of 9-bromomethyl-3-cyano-4H-­ pyrido[l,2-a]pyrimidin-4-one, 0.97 g (5.00 mmoles) of 2,4-­ dihydroxy-3-n-propylacetophenone and 0.60 g of anhydrous potassium carbonate were added to l00 mℓ of methyl ethyl ketone, and this mixture was heated under reflux for 45 minutes. After cooling, the crystals which separated out of the reaction solution were collected by filtration and washed with water to obtain l.l0 g (59% yield) of 9-[(4-­ acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-cyano-4H-­ pyrido[l,2-a]pyrimidin-4-one. These crystals had a melting point of 233-234°C. The following l8 nitrile derivatives [II] were prepared in substantially the same manner as described above, except that the 9-bromomethyl-3-cyano-4H-pyrido[l,2-a]pyrimidin-4-­ one was replaced by each of the corresponding compounds [III] and the reaction conditions (such as the molar ratio of reactants, reaction solvent, reaction temperature, reaction time, etc.) were suitably modified. Thus, these nitrile derivatives [II] were obtained in a yield ranging from 50% to 85%: 7-[(4-A-etyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-cyano-­ 4H-pyrido[l,2-a]pyrimidin-4-one. 8-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-cyano-­ 4H-pyrido[l,2-a]pyrimidin-4-one. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-7-bromo-­ 3-cyano-4H-pyrido[l,2-a]pyrimidin-4-one. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-cyano-­ 7-methyl-4H-pyrido[l,2-a]pyrimidin-4-one. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-­ cyanomethyl-4H-pyrido[l,2-a]pyrimidin-4-one. 7-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-­ cyanomethyl-4H-pyrido[l,2-a]pyrimidin-4-one. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-­ cyanomethyl-7-methyl-4H-pyrido[l,2-a]pyrimidin-4-one. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-­ (2-cyanoethyl)-4H-pyrido[l,2-a]pyrimidin-4-one. 8-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-­ (2-cyanoethyl)-4H-pyrido[l,2-a]pyrimidin-4-one. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-7-­ bromo-3-(2-cyanoethyl)-4H-pyrido[l,2-a]pyrimidin-4-one. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-8-­ chloro-3-cyano-4H-pyrido[l,2-a]pyrimidin-4-one. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-­ cyano-6-fluoro-4H-pyrido[l,2-a]pyrimidin-4-one. 7-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-8-­ chloro-3-cyano-4H-pyrido[l,2-a]pyrimidin-4-one. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-­ cyano-8-methyl-4H-pyrido[l,2-a]pyrimidin-4-one. 7-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-8-­ bromo-3-cyanomethyl-4H-pyrido[l,2-a]pyrimidin-4-one. 8-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-9-­ chloro-3-cyanomethyl-4H-pyrido[l,2-a]pyrimidin-4-one. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyi]-3-­ (2-cyanoethyl)-6-fluoro-4H-pyrido[l,2-a]pyrimidin-4-one. 7-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyi]-3-­ (2-cyanoethyl)-8-methyl-4H-pyrido[l,2-a]pyrimidin-4-one. Example l (Procedure a ) A mixture of l.00 g (2.65 mmoles) of 9-[(4-acetyl-3-­ hydroxy-2-n-propylphenoxy)methyl]-3-cyano-4H-pyrido[l,2-a]-­ pyrimidin-4-one, 0.97 g (7.27 mmoles) of aluminum chloride, l.43 g (2l.99 mmoles) of sodium azide and 20 mℓ of tetrahydrofuran was heated under reflux for 2 hours. After cooling, the resulting reaction solution was diluted with ice water and then acidified with dilute hydrochloric acid. The precipitate so formed was collected by filtration and recrystallized from dimethylformamide to obtain 0.72 g (65% yield) of 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-­ 3-(lH-tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one in the form of white crystals. These crystals had a melting point of 269-27l°C (dec.). (Procedure b ) A mixture of l.00 g (2.65 mmoles) of 9-[(4-acetyl-3-­ hydroxy-2-n-propylphenoxy)methyl]-3-cyano-4H-pyrido[l,2-a]-­ pyrimidin-4-one, 0.97 g (7.27 mmoles) of aluminum chloride, l.43 g (2l.99 mmoles) of sodium azide and 20 mℓ of tetrahydrofuran was heated under reflux for 2 hours. After cooling, the resulting reaction solution was diluted with ice water and then acidified with dilute hydrochloric acid. The precipitate so formed was collected by filtration and dried. l.09 g (2.59 mmoles) of this precipitate was suspended in 55 mℓ of methanol and then dissolved therein by adding 3.00 mℓ (2.55 mmoles) of a 5.6% ethanolic solution of potassium hydroxide. The resulting solution was filtered to remove any insoluble matter, and the filtrate was cooled. The precipitate which separated out was collected by filtra­ tion to obtain 0.88 g (74% yield) of 9-[(4-acetyl-3-hydroxy-­ 2-n-propylphenoxy)methyl]-3-(lH-tetrazol-5-yl)-4H-pyrido[l,2-­ a]pyrimidin-4-one potassium salt. Subsequently, 0.88 g (l.92 mmoles) of this potassium salt was dissolved in l80 mℓ of water by warming and the resulting solution was neutralized with l.23 mℓ (3.69 mmoles) of 3N hydrochloric acid. The precipitate so formed was collected by filtration to obtain 0.78 g (97% yield) of 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)-­ methyl]-3-(lH-tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one in the form of a white powder. This powder had a melting point of 268-27l°C (dec.) and its infrared absorption spectrum and elemental analysis were as follows: The compounds of the following Examples 2-5 were prepared by repeating the above-described procedure a of Example l except that the 9-[(4-acetyl-3-hydroxy-2-n-­ propylphenoxy)methyl]-3-cyano-4H-pyrido[l,2-a]pyrimidin-­ 4-one (2.65 mmoles) was replaced by each of the corresponding nitrile derivatives [II] (2.65 mmoles). Example 2 There was obtained 0.l9 g (l7% yield) of 7-[(4-acetyl-­ 3-hydroxy-2-n-propylphenoxy)methyl]-3-(lH-tetrazol-5-yl)-­ 4H-pyrido[l,2-a]pyrimidin-4-one in the form of white crystals. These crystals, which were recrystallized from acetonitrile, had a melting point of 256-260°C (dec.). Example 3 There was obtained 0.26 g (23% yield) of 8-[(4-acetyl-­ 3-hydroxy-2-n-propylphenoxy)methyl]-3-(lH-tetrazol-5-yl)-­ 4H-pyrido[l,2-a]pyrimidin-4-one in the form of white crystals. These crystals, which were recrystallized from dimethylformamide, had a melting point of 263-272°C (dec.). Example 4 There was obtained 0.l2 g (9% yield) of 9-[(4-acetyl-­ 3-hydroxy-2-n-propylphenoxy)methyl]-7-bromo-3-(lH-tetrazol-­ 5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one in the form of pale-­ yellow crystals. These crystals, which were recrystallized from a mixture of tetrahydrofuran and methanol, had a melting point of 240°C (dec.). Example 5 There was obtained 0.59 g (5l% yield) of 9-[(4-acetyl-­ 3-hydroxy-2-n-propylphenoxy)methyl]-7-methyl-3-(lH-tetrazol-­ 5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one in the form of white crystals. These crystals, which were recrystallized from dimethylformamide, had a melting point of 279-280°C (dec.). Example 6 (Procedure a ) A mixture of l.04 g (2.65 mmoles) of 9-[(4-acetyl-3-­ hydroxy-2-n-propylphenoxy)methyl]-3-cyanomethyl-4H-pyrido[l,2-­ a]pyrimidin-4-one, l.00 g (l8.69 mmoles) of ammonium chloride, l.2l g (l8.6l mmoles) of sodium azide and 30 mℓ of dimethyl­ formamide was heated at l00-ll0°C for 8 hours with stirring. After cooling, the resulting reaction solution was poured into ice water and then acidified with dilute hydrochloric acid. The precipitate so formed was collected by filtration and recrystallized from dimethylformamide to obtain 0.55 g (48% yield) of 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)-­ methyl]-3-[(lH-tetrazol-5-yl)methyl]-4H-pyrido[l,2-a]pyrimidin-­ 4-one in the form of pale-yellow crystals. These crystals had a melting point of 250-253°C (dec.). Procedure b A mixture of l.04 g (2.65 mmoles) of 9-[(4-acetyl-3-­ hydroxy-2-n-propylphenoxy)methyl]-3-cyanomethyl-4H-pyrido[l,2-­ a]pyrimidin-4-one, l.00 g (l8.69 mmoles) of ammonium chloride, l.2l g (l8.6l mmoles) of sodium azide and 30 mℓ of dimethyl­ formamide was heated at l00-ll0°C for 8 hours with stirring. After cooling, the resulting reaction solution was poured into ice water and then acidified with dilute hydrochloric acid. The precipitate so formed was collected by filtration and then dried. l.l0 g (2.53 mmoles) of this precipitate was suspended in 70 mℓ of methanol and dissolved therein by adding 2.30 mℓ (2.30 mmoles) of a 4.2% aqueous solution of sodium hydroxide. The resulting solution was filtered to remove any insoluble matter. The filtrate was evaporated to dryness under reduced pressure to obtain l.05 g (9l% yield) of 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-[(lH-­ tetrazol-5-yl)methyl]-4H-pyrido[l,2-a]pyrimidin-4-one sodium salt. Subsequently, l.05 g (2.30 mmoles) of this sodium salt was dissolved in 260 mℓ of water and the resulting solution was neutralized with l.50 mℓ (4.50 mmoles) of 3N hydrochloric acid. The precipitate so formed was collected by filtration and then dried to obtain 0.97 g (97% yield) of 9-[(4-acetyl-3-­ hydroxy-2-n-propylphenoxy)methyl]-3-[(lH-tetrazol-5-yl)methyl]-­ 4H-pyrido[l,2-a]pyrimidin-4-one in the form of a pale-yellow powder. This powder had a melting point of 248-253°C (dec.) and its infrared absorption spectrum and elemental analysis were as follows: The compounds of the following Examples 7 and 8 were prepared by repeating the above-described procedure a of Example 6 except that the 9-[(4-acetyl-3-hydroxy-2-n-­ propylphenoxy)methyl]-3-cyanomethyl-4H-pyrido[l,2-a]pyrimidin-­ 4-one (2.65 mmoles) was replaced by each of the corresponding nitrile derivatives [II] (2.65 mmoles). Example 7 There was obtained 0.44 g (38% yield) of 7-[(4-acetyl-­ 3-hydroxy-2-n-propylphenoxy-methyl]-3-[(lH-tetrazol-5-yl)-­ methyl]-4H-pyrido[l,2-a]pyrimidin-4-one in the form of pale-­ yellow crystals. These crystals, which were recrystallized from acetic acid, had a melting point of 228-232°C (dec.). Example 8 There was obtained 0.62 g (52% yield) of 9-[(4-acetyl-3-­ hydroxy-2-n-propylphenoxy)methyl]-7-methyl-3-[(lH-tetrazol-5-­ yl)methyl]-4H-pyrido[l,2-a]pyrimidin-4-one in the form of white crystals. These crystals, which were recrystallized from dimethylformamide, had a melting point of 234-238°C (dec.). Example 9 (Procedure a ) A mixture of l.07 g (2.65 mmoles) of 9-[(4-acetyl-3-­ hydroxy-2-n-propylphenoxy)methyl]-3-(2-cyanoethyl)-4H-­ pyrido[l,2-a]pyrimidin-4-one, l.76 g (l3.20 mmoles) of aluminum chloride, 2.57 g (39.53 mmoles) of sodium azide and 45 mℓ of tetrahydrofuran was heated under reflux for 23 hours. After cooling, the resulting reaction solution was poured into ice water and then acidified with dilute hydrochloric acid. The precipitate so formed was separated by filtration and recrystallized from acetonitrile to obtain 0.70 g (59% yield) of 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-­ [2-(lH-tetrazol-5-yl)ethyl]-4H-pyrido[l,2-a]pyrimidin-4-one in the form of white crystals. These crystals had a melting point of 238-239°C (dec.). (Procedure b ) A mixture of l.07 g (2.65 mmoles) of 9-[(4-acetyl-3-­ hydroxy-2-n-propylphenoxy)methyl]-3-(2-cyanoethyl)-4H-­ pyrido[l,2-a]pyrimidin-4-one, l.76 g (l3.20 mmoles) of aluminum chloride, 2.57 g (39.53 mmoles) of sodium azide and 45 mℓ of tetrahydrofuran was heated under reflux for 23 hours. After cooling, the resulting reaction solution was poured into ice water and then acidified with dilute hydrochloric acid. The precipitate so formed was separated by filtration and then dried. l.l4 g (2.54 mmoles) of this precipitate was suspended in 250 mℓ of water and dissolved therein by adding 2.69 mℓ (2.29 mmoles) of a 5.6% aqueous solution of potassium hydroxide. After the resulting solution was filtered to remove any insoluble matter, the filtrate was freeze-dried to obtain l.ll g (90% yield) of 9-[(4-acetyl-3-hydroxy-2-n-­ propylphenoxy)methyl]-3-[2-(lH-tetrazol-5-yl)ethyl]-4H-­ pyrido[l,2-a]pyrimidin-4-one potassium salt. Subsequently, l.ll g (2.28 mmoles) of this potassium salt was dissolved in 250 mℓ of water and the resulting solution was neutralized with l.50 mℓ (4.50 mmoles) of 3N hydrochloric acid. The precipitate so formed was collected by filtration and then dried to obtain l.00 g (98% yield) of 9-[(4-acetyl-3-hydroxy-­ 2-n-propylphenoxy)methyl]-3-[2-(lH-tetrazol-5-yl)ethyl]-4H-­ pyrido[l,2-a]pyrimidin-4-one in the form of a white powder. This powder had a melting point of 236-239°C (dec.) and its infrared absorption spectrum and elemental analysis were as follows: The compounds of the following Examples l0 and ll were prepared by repeating the above-described procedure a of Example 9 except that the 9-[(4-acetyl-3-hydroxy-2-n-­ propylphenoxy)methyl]-3-(2-cyanoethyl)-4H-pyrido[l,2-a]-­ pyrimidin-4-one (2.65 mmoles) was replaced by each of the corresponding nitrile derivatives [II] (2.65 mmoles). Example l0 There was obtained 0.43 g (36% yield) of 8-[(4-acetyl-­ 3-hydroxy-2-n-propylphenoxy)methyl]-3-[2-(lH-tetrazol-5-yl)-­ ethyl]-4H-pyrido[l,2-a]pyrimidin-4-one in the form of white crystals. These crystals, which were recrystallized from dimethylformamide, had a melting point of 226-230°C (dec.). Example ll There was obtained 0.25 g (l8% yield) of 9-[(4-acetyl-3-­ hydroxy-2-n-propylphenoxy)methyl]-7-bromo-3-[2-(lH-tetrazol-­ 5-yl)ethyl]-4H-pyrido[l,2-a]pyrimidin-4-one in the form of pale-yellow crystals. These crystals, which were recrystallized from acetonitrile, had a melting point of 220-223°C (dec.). Example l2 l.00 g (2.38 mmoles) of 9-[(4-acetyl-3-hydroxy-2-n-­ propylphenoxy) methyl]-3-(lH-tetrazol-5-yl)-4H-pyrido[l,2-a]-­ pyrimidin-4-one was suspended in 50 mℓ of methanol and dissolved therein by adding 2.75 mℓ (2.34 mmoles) of a 5.6% ethanolic solution of potassium hydroxide. The resulting solution was filtered to remove any insoluble matter, and the filtrate was cooled. The precipitate which separated out was collected by filtration to obtain 0.8l g (74% yield) of 9-­ [(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-(lH-­ tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one potassium salt in the form of a pale-yellow powder. Example l3 l.00 g (2.23 mmoles) of 9-[(4-acetyl-3-hydroxy-2-n-­ propylphenoxy) methyl]-3-[2-(lH-tetrazol-5-yl)ethyl]-4H-­ pyrido[l,2-a]pyrimidin-4-one was suspended in 200 mℓ of water and dissolved therein by adding 2.62 mℓ (2.23 mmoles) of a 5.6% aqueous solution of potassium hydroxide. The resulting solution was filtered to remove any insoluble matter, and the filtrate was freeze-dried to obtain l.06 g (98% yield) of 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-[2-(lH-­ tetrazol-5-yl)ethyl]-4H-pyrido[l,2-a]pyrimidin-4-one potassium salt in the form of a pale-yellow powder. In addition, the nine compounds enumerated below were prepared in substantially the same manner as described above in Examples l, 6, 9 and l3. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-8-­ chloro-3-(lH-tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-6-­ fluoro-3-(lH-tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one. 7-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-8-­ chloro-3-(lH-tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-8-­ methyl-3-(lH-tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one. 7-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-8-­ bromo-3-[(lH-tetrazol-5-yl)methyl]-4H-pyrido[l,2-a]pyrimidin-­ 4-one. 8-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-9-­ chloro-3-[(lH-tetrazol-5-yl)methyl]-4H-pyrido[l,2-a]pyrimidin-­ 4-one. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-6-­ fluoro-3-[2-(lH-tetrazol-5-yl)ethyl]-4H-pyrido[l,2-a]pyrimidin-­ 4-one. 7-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-8-­ methyl-3-[2-(lH-tetrazol-5-yl)ethyl]-4H-pyrido[l,2-a]pyrimidin-­ 4-one. 9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-­ [(lH-tetrazol-5-yl)methyl]-4H-pyrido[l,2-a]pyrimidin-4-one sodium salt. The above ingredients (l)-(5) were blended together. After the addition of water, the resulting mixture was granulated and then dried. The granules so formed were adjusted to a predetermined size range, and the ingredient (6) was added thereto. The resulting mixture was compressed to form tablets each containing l0 mg of the active ingredient. Other tablets were also prepared in the same manner as described above, except that the compound of Example l used as the active ingredient was replaced by each of the compounds of Examples 6 and 9 (both prepared according to procedure b ). According to conventional procedure, the above ingredients were blended together and then granulated. The granules so formed were filled into capsules, each of which contained l0 mg of the active ingredient. Other capsules were also prepared in the same manner as described above, except that the compound of Example 9 used as the active ingredient was replaced by each of the compounds of Examples l and 6 (both prepared according to procedure b ).

Claims: 1. A pyrido[l,2-a]pyrimidine derivative of the general formula where R is a hydrogen atom, a halogen atom or a methyl group, and n is 0, l or 2, or a physiologically acceptable salt thereof. 2. A compound as claimed in claim l which is any one of the following compounds, 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-(lH-­ tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one, 7-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-(lH-­ tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one, 8-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-(lH-­ tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one, 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-7-bromo-­ 3-(lH-tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one, 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-7-methyl-­ 3-(lH-tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one, 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-[lH-­ tetrazol-5-yl)methyl]-4H-pyrido[l,2-a]pyrimidin-4-one, 7-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-[lH-­ tetrazol-5-yl)methyl]-4H-pyrido[l,2-a]pyrimidin-4-one, 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-7-methyl-­ 3-[(lH-tetrazol-5-yl)methyl]-4H-pyrido[l,2-a]pyrimidin-4-one, 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-[2-(lH-­ tetrazol-5-yl)ethyl]-4H-pyrido[l,2-a]pyrimidin-4-one, 8-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-[2-(lH-­ tetrazol-5-yl)ethyl]-4H-pyrido[l,2-a]pyrimidin-4-one or 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-7-bromo-­ 3-[2-(lH-tetrazol-5-yl)ethyl]-4H-pyrido[l,2-a]pyrimidin-4-one. 3. A compound as claimed in claim l wherein the physiologically acceptable salt is a potassium or sodium salt. 4. A compound as claimed in claim 3 which is 9-[(4-­ acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-(lH-tetrazol-5-­ yl)-4H-pyrido[l,2-a]pyrimidin-4-one potassium salt or 9-[(4-­ acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-[2-(lH-tetrazol-­ 5-yl)ethyl]-4H-pyrido[l,2-a]pyrimidin-4-one potassium salt. 5. A process for preparing pyrido[l,2-a]pyrimidine derivatives of general formula where R is a hydrogen atom, a halogen atom or a methyl group, and n is 0, l or 2, and physiologically acceptable salts thereof, which comprises reacting a nitrile derivative of general formula where R and n are as previously defined, with hydrazoic acid or a salt thereof. and then optionally forming a salt thereof. 6. A process as claimed in claim 5 wherein the salt of hydrazoic acid is aluminum azide or ammonium azide formed in the reaction system by using sodium azide in combination with aluminum chloride or ammonium chloride, respectively. 7. A process as claimed in either of claims 5 and 6 wherein the treatment for the formation of a salt is carried out by using potassium hydroxide or sodium hydroxide. 8. A pharmaceutical composition comprising a pyrido[l,2-a]pyrimidine derivative of general formula where R is a hydrogen atom, a halogen atom or a methyl group, and n is 0, l or 2, or a physiologically acceptable salt thereof. 9. A pharmaceutical composition as claimed in claim 8 or 9 wherein the compound of formula I is selected from the group consisting of 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-­ 3-(lH-tetrazol-5-yl)-4H-pyrido[l,2-a]pyrimidin-4-one, 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-[(lH-­ tetrazol-5-yl)methyl]-4H-pyrido[l,2-a]pyrimidin-4-one and 9-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-[2-(lH-­ tetrazol-5-yl)ethyl]-4H-pyrido[l,2-a]pyrimidin-4-one, as well as the potassium salts thereof. l0. The use of a compound as claimed in any one of claims l to 4 for the manufacture of a medicament for the treatment of allergic diseases. 11. The use as claimed in claim l0 wherein the allergic disease is bronchial asthma and/or allergic rhinitis. Claims for the following Contracting States:AT;ES;GR 1. A process for preparing a pyrido[l,2-a]pyrimidine derivative of general formula [I]: where R is a hydrogen atom, a halogen atom or a methyl group, and n is 0, l or 2 or a physiologically acceptable salt thereof, which comprises reacting a nitrile derivative of general formula [II]: where R and n are as previously defined, with hydrazoic acid or a salt thereof; and then optionallyforming a salt thereof. 2. A process as claimed in claim l wherein the salt of hydrazoic acid is an alkali metal salt selected from the group consisting of sodium azide and potassium azide, an alkaline-­ earth metal salt selected from the group consisting of calcium azide and magnesium azide, a salt formed by reaction with other metal selected from the group consisting of aluminum azide, tin azide and titanium azide or a salt formed by reaction with an organic base selected from the group consisting of ammonium azide and aniline azide. 3. A process as claimed in claim 2 wherein the alkali metal salt is used in combination with a Lewis acid such as aluminum chloride or tin chloride, or a suitable salt such as ammonium chloride or aniline chloride to be converted into aluminum azide, tin azide, ammonium azide or aniline azide in the reaction system. 4. A process as claimed in any one of claims l, 2 and 3 wherein the reaction is carried out in a reaction solvent selected from the group consisting of tetrahydrofuran, dioxane, dimethylformamide, dimethyl sulfoxide, dimethyl­ acetamide, hexamethylphosphorotriamide for l minute to 72 hours at a temperature of 50 to l50°C. 5. A process as claimed in any one of claims l to 4 where a resulting compound of formula [I] as defined in claim l is purified by converting it to a suitable salt thereof and then neutralizing this salt to effect crystallization. 6. A process as claimed in claim 5 wherein the suitable salt is sodium salt, potassium salt, calcium salt, magnesium salt or ammonium salt, and the neutralizing agent is hydrochloric acid, sulfuric acid, nitric acid, acetic acid or formic acid. 7. A process as claimed in any one of claims l to 4 wherein the treatment for the formation of a salt is carried out by using sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium alcoholate or potassium alcoholate. 8. A process as claimed in claim l where the nitrile derivative of formula [II] as defined in claim l is prepared by condensing l mole of a compound of general formula [III]: where R and n are as defined in claim l, and X is a chlorine or bromine atom, with l to 6 moles of 2,4-dihydroxy-3-n-­ propylacetophenone in the presence of an acid acceptor. 9. A process for preparing a pharmaceutical composition useful for the treatment of allergic diseases which comprises admixing a compound of formula [I] as defined in claim l or a physiologically acceptable salt thereof with one or more physiologically inert solid or liquid pharmaceutical carriers. l0. A process as claimed in claim 9 wherein the allergic diseases include bronchial asthma and allergic rhinitis.

Inventors: AMANO, MICHIAKI, KAKEHI, NORIHIKO, KAWASHIMA, TOSHIO 2-19-310, WASHIMIYA-DANCHI, MATSUISHI, NAOTO, NAKAGAWA, YOSHIO, OMURA, SHIGEKI SETAGAYA'S COMPANY RESIDENCE OF
Applicants: TOKYO TANABE COMPANY LIMITED
Application year: 1986
Main classification: C07D471
IPC codes: A61P9, A61K31, A61P11, C07D471, A61P43, A61P1, A61P29, A61P37